This turnkey end-to-end monoclonal antibody (mAb) manufacturing line covers the complete workflow from cell line revival, seed expansion, upstream fed-batch/perfusion cell culture, bioreactor harvest & clarification, intermediate concentration, multi-step chromatography purification, viral inactivation, polishing, ultrafiltration-diafiltration formulation to final bulk drug substance sterile filtration and holding.
The upstream segment adopts scalable stirred-tank or single-use bioreactor systems, matched with automated media & buffer preparation skids, enabling stable high-density CHO cell cultivation, high antibody expression titre and consistent batch reproducibility. Continuous-flow or disc stack centrifuges paired with depth filters perform efficient cell broth clarification, lowering solid load for subsequent purification steps.
Downstream workflow integrates multi-stage chromatography units, automated inline buffer formulation skids and automated TFF UF/DF systems, accomplishing target antibody capture, impurity removal, viral clearance, aggregate reduction and buffer exchange. Fully closed sanitary fluid pathways eliminate open operations and cross-contamination risks; all core process equipment supports CIP/SIP or single-use disposable flow paths, flexible enough for multi-product campaign switching.
Equipped with unified central PLC control system, recipe management, full batch data logging, audit trails and electronic signature functions, the entire line strictly complies with cGMP, FDA and EMA guidelines as well as 21 CFR Part 11 data integrity requirements. Factory FAT and on-site SAT full qualification support smooth validation execution. Modular layout design allows phased capacity expansion, suitable for clinical trial material production, pilot scale-up and full commercial mAb bulk drug substance manufacturing, helping biopharma clients rapidly realise industrialised stable antibody mass production.
